TAUNS Laboratories, Inc.
197A.T · JPX
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.16 | 0.09 | -0.43 | 0.00 |
| FCF Yield | 3.90% | 13.40% | -10.32% | 20.03% |
| EV / EBITDA | 6.64 | 5.17 | 8.86 | 4.73 |
| Quality | ||||
| ROIC | 19.52% | 24.64% | 19.60% | 45.30% |
| Gross Margin | 66.17% | 67.80% | 56.06% | 81.84% |
| Cash Conversion Ratio | 1.08 | 1.72 | -1.04 | 2.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.93% | 1.83% | 25,025,526.52% | 25,941,082.13% |
| Free Cash Flow Growth | -64.22% | 238.18% | -151.50% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | 0.01 | 0.98 | -0.17 |
| Interest Coverage | 80.32 | 257.28 | 227.76 | 1,335.59 |
| Efficiency | ||||
| Inventory Turnover | 1.07 | 1.26 | 1.50 | 0.69 |
| Cash Conversion Cycle | 276.16 | 252.48 | 253.57 | 387.92 |